Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 11,406 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: SCID
Interventions: Busulfan, Cell processing for TCRαβ+/CD19+ depletion; Drug · Device
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 0 Years to 2 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Classical Hodgkin Lymphoma
Interventions: Tenalisib, Pembrolizumab; Drug · Biological
Lead sponsor: Rhizen Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois • Detroit, Michigan • Seattle, Washington

Conditions: Spinal Injuries, Adhesions
Interventions: DuraGen Plus Adhesion Barrier Matrix; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 36
States / cities: Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 31 more

Conditions: Colorectal Neoplasms
Interventions: Veterans Affairs Endoscopy Quality Improvement Program (VA-EQuIP); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • Indianapolis, Indiana + 3 more

Conditions: Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
Interventions: Not listed
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Seattle, Washington

Conditions: Hemophilia A
Interventions: Emicizumab, Factor VIII (FVIII); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 8
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 36
States / cities: Birmingham, Alabama • Oakland, California • Palo Alto, California + 33 more

Conditions: Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
Interventions: CUE-101, KEYTRUDA®, Pembrolizumab; Drug
Lead sponsor: Cue Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 17
States / cities: Tucson, Arizona • Palo Alto, California • New Haven, Connecticut + 14 more

Conditions: Proliferative Diabetic Retinopathy
Interventions: Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation; Other · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 48
States / cities: Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Spinal Cord Injuries
Interventions: Sprint Interval Training (SIT), Usual Care, Home Ergometer (ERGO), Motivational Interviewing (MI); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more

Conditions: Lupus Nephritis
Interventions: BMS-986165, Placebo, Mycophenolate Mofetil; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 40
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more

Conditions: Squamous Cell Lung Cancer
Interventions: gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 61 more

Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions: Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD); Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 12 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab 300 mg, Anifrolumab 1000 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • La Jolla, California • La Palma, California + 27 more

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: pegfilgrastim, carboplatin, docetaxel; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Depressive Disorder
Interventions: Depression Care Management; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more

Conditions: Defibrillators, Implantable, Heart Failure, Congestive
Interventions: Aerobic Exercise Program; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Interventions: Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Bortezomib, Melphalan, Prednisone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 14
States / cities: Fresno, California • Greenbrae, California • Modesto, California + 11 more

Conditions: Lymphoma, Mantle Cell
Interventions: Acalabrutinib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 65 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 32
States / cities: Tucson, Arizona • Downey, California • Santa Monica, California + 27 more

Conditions: Dry Age-related Macular Degeneration
Interventions: GT005; Drug
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more

Search by objective public record fields.

Conditioning SCID Infants Diagnosed Early

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery

Improving Colonoscopy Quality for Colorectal Cancer Screening in the National VA Healthcare System

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Rollover Study of VX-770 in Cystic Fibrosis Subjects

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Feasibility of a Sprint Interval Training Program During Inpatient Spinal Cord Injury Rehabilitation

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Depression Attention for Women Now (The DAWN Study)

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

Exercise After an ICD

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005